As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.

Lilly's-Biotechnology-Center-San-Diego
At Lilly, sales volume is up but revenue is down

Eli Lilly and Company is bullish on the launch metrics for its GIP/GLP-1 agonist Mounjaro (tirzepatide) in type 2 diabetes, which is the first of five new products it hopes to launch before the end of 2023, including the Alzheimer’s disease candidate donanemab. But while impressed by Mounjaro’s quick start, analysts had trouble getting past Lilly’s quarterly sales decline of 4%, which the pharma attributed mainly to pricing pressures in the US and elsewhere, along with the impact of foreign exchange.

CEO David Ricks also stepped up again on the soapbox during Lilly’s Q2 earnings call on 4 August to criticize...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.